WO2001087277A2 - Procede de fabrication de particules - Google Patents

Procede de fabrication de particules Download PDF

Info

Publication number
WO2001087277A2
WO2001087277A2 PCT/GB2001/002137 GB0102137W WO0187277A2 WO 2001087277 A2 WO2001087277 A2 WO 2001087277A2 GB 0102137 W GB0102137 W GB 0102137W WO 0187277 A2 WO0187277 A2 WO 0187277A2
Authority
WO
WIPO (PCT)
Prior art keywords
particles
solution
low
boiling fraction
active substance
Prior art date
Application number
PCT/GB2001/002137
Other languages
English (en)
Other versions
WO2001087277A3 (fr
Inventor
David Alexander Vodden Morton
Original Assignee
Vectura Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0011712A external-priority patent/GB0011712D0/en
Priority claimed from GB0029265A external-priority patent/GB0029265D0/en
Application filed by Vectura Limited filed Critical Vectura Limited
Priority to AU2001254995A priority Critical patent/AU2001254995A1/en
Publication of WO2001087277A2 publication Critical patent/WO2001087277A2/fr
Publication of WO2001087277A3 publication Critical patent/WO2001087277A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Definitions

  • the present invention relates to particles and to methods
  • the invention relates to methods of making particles comprising a pharmaceutical substance .
  • -0 particulate medicament composition is inhaled by the patient.
  • the particles In order that the particles be carried deep into the lungs, the particles must be very fine, for example having an aerodynamic diameter of less than lO ⁇ m. Pulmonary administration is particularly suitable for medicaments which
  • .5 are intended to cure or alleviate respiratory conditions such as asthma and for medicaments which are not suitable for oral ingestion such as certain biological macromolecules.
  • Medicament compositions in the form of particles may also be administered via needle-less injection.
  • Fine medicament particles suitable for pulmonary administration have been prepared by milling. However, it is difficult to control the morphology, size distribution, shape, density and other physical properties of the particles during the milling process.
  • Fine medicament particles have also been prepared by spray drying.
  • W09741833 describes a method for the manufacture of fine particles comprising biological macromolecules in which the biological macromolecules are slurried or dissolved in a liquid medium, usually an aqueous 0 medium, which is then atomised in a heated gas stream so that the liquid evaporates to form particles.
  • Supercritical fluids have been used in the production of aerosols for the precipitation of fine solid particles. Such methods have relied on the increased solubilising ability of compressed fluids above their critical temperature and pressure and the loss of that property upon reduction in pressure below the critical point . Fluids used include those which are gases at standard temperature and pressure and the most commonly used fluid is carbon dioxide.
  • US5639441 discloses a method wherein a supercritical fluid and a solution of an active substance are mixed to give an immiscible mixture. That mixture is passed through an orifice into a low pressure region causing the precipitation of the active substance as fine particles.
  • the present invention provides a method of preparing a powder comprising particles comprising an active substance, the method comprising the steps of providing a solution comprising the active substance and a low-boiling fraction, expelling the solution through an orifice to form droplets, allowing the low-boiling fraction to evaporate, particles comprising the active substance being formed and collecting the particles as a powder.
  • the powder may be used directly as a medicament or may be subject to further treatment steps.
  • the powder may be combined with other materials such as flow aids.
  • the major part and preferably substantially all of the active substance will be dissolved.
  • the powders will be dry powders, that is the water content will be less than about 20%, preferably 10% and more preferably 5% by weight of the powder immediately after collection.
  • low-boiling fraction will be understood to refer to any compound having a boiling point below 20 °C at atmospheric pressure or to any combination of such compounds. Furthermore, the low boiling fraction will be understood not to be heated and pressurised above its critical point, that is, it will not be supercritical.
  • the use of such a low- boiling fraction allows the evaporation and consequent formation of the particles to be carried out at ambient temperatures or at temperatures only slightly above ambient temperatures, for example at temperatures of 20 to 25°C or slightly above. Such temperatures are particularly suitable for the manufacture of powders comprising temperature- sensitive substances such as proteins, although the invention is not limited to such powders.
  • the air inlet temperature will generally be more than 50°C and often in excess of 100°C to ensure full evaporation.
  • a further advantage over conventional spray drying of aqueous solutions is that the solutions used in the method of the invention will often have a comparatively low surface tension and/or viscosity and in consequence the method of the invention will often require a comparatively low amount of energy and deliver smaller particles with less degradation of the active substance due to shear forces .
  • the orifice is located in a nozzle, for example, a nozzle suitable for use in a spray dryer.
  • the rapid generation of vapour will assist in dispersing the solution stream into droplets and it is therefore possible to operate the method of the invention using simple apparatus .
  • the orifice is a single fluid nozzle.
  • nozzles commonly used in spray drying for example, two fluid nozzles (which expel, for example, an aqueous liquid and a stream of air, the air being required to disperse the aqueous liquid into droplets) , spinning disc nozzles and ultrasonic nozzles are not always required but may be advantageously used in some cases.
  • a two fluid nozzle may be employed where it is desired to have a carrier gas to provide additional dilution.
  • the low-boiling fraction starts to vapourise, such that a proportion of the low-boiling fraction forms vapour bubbles within the liquid. Those bubbles expand rapidly and coalesce to form a high pressure and high velocity vapour stream which accompanies the liquid on exit from the nozzle. That vapour stream performs, at least to some extent, the same function as the driving gas of a two fluid nozzle, that is, it creates the shear force at the nozzle to provide the primary break-up of the solution. As the solution passes through the orifice, it forms into films which extend from the surfaces of the nozzle around the orifice.
  • Droplets are formed by vapour flow stripping liquid from the films. Secondary droplets are subsequently formed in the vapour stream, from suspended liquid filaments which are shattered by the high velocity vapour flow, and from bubbles bursting from liquid droplets of larger size. Assuming further fragmentation does not occur, and no solid condensation or particle-particle collisions occur, the resulting particle mass from a drying droplet is dependent on the non-volatile solute and solid mass contained within the droplet.
  • the above description of the formation of the droplets and particles is for the purpose of illustration only and is not to be taken as limiting the invention.
  • the aerosol cloud formed from the spray is very dynamic and rapidly evolving.
  • the evolution includes dramatic shrinkage in size of the droplets and changes in velocity over a relatively short time period.
  • the reproducibility is remarkably consistent, so that a given set of conditions will consistently provide particles of similar mass on different 5 occasions.
  • the low-boiling fraction comprises at least 10%, advantageously at least 30% and more preferably at least 50%, more advantageously at least 70% and most preferably at least 90% of the solution by weight.
  • the solution preferably
  • LO comprises less than 99.99% by weight of the low boiling fraction.
  • the low-boiling fraction consists of one or more compounds having a boiling point (at atmospheric pressure) below 20°C, advantageously below 10°C and preferably below 0 C.
  • the low-boiling fraction may consist of one or more compounds having a boiling point (at atmospheric pressure) in the range of -100°C to 20°C, advantageously in the range of -60 °C to 20 °C, preferably in the range of -50°C to 10°C and especially between -45°C and -10°C.
  • the low-boiling fraction comprises a propellant suitable for use in aerosol formation and preferably the low-boiling fraction comprises a propellant suitable for use in an aerosol can device or a pressurised metered dose inhaler. Examples of suitable propellants and
  • the low-boiling fraction is preferably non-toxic. However, the low boiling fraction may comprise pharmaceutically unacceptable compounds as long as those compounds fully evaporate so that the particles are essentially free of those compounds. Preferably the low- boiling fraction is non-flammable.
  • the low-boiling fraction may comprise a halogenated hydrocarbon, especially a hydrofluoroalkane such as HFA 134a or HFA 227 or a mixture thereof .
  • the solution may comprise only the active substance and the low-boiling fraction. In that case, the solution may be prepared simply by dissolving the active substance in the low- boiling fraction.
  • the solution may also comprise one or more co-solvents.
  • co-solvent is to be understood as including any solvent or solvent system which enhances the solubility of the active substance in the low-boiling fraction.
  • Co-solvents will normally be polar liquids.
  • Suitable co-solvents include, for example water, any one of or combination of organic solvents such as alcohols (e.g. methanol , ethanol) , ethers, halogenated hydrocarbons (dichloromethane, chloroform etc) , which provide a variable solvation capability, altering the polarity of the liquid appropriate to allow the solvation of the active substance.
  • alcohols e.g. methanol , ethanol
  • ethers e.g. ethers
  • halogenated hydrocarbons e.g. halogenated hydrocarbons (dichloromethane, chloroform etc)
  • Many suitable solvents are non-toxic and physiologically tolerable.
  • Co-solvents which are toxic or otherwise pharmaceutically unacceptable may, however, be used as long as they may be fully evaporated from the particles, either during the spray process or in a post-process conditioning.
  • a co-solvent will be required where the active substance is not soluble to the required degree in the low- boiling fraction alone.
  • the low-boiling fraction consists of HFA 134a or HFA 227 or a mixture thereof, it will sometimes be necessary to add a co- solvent such as ethanol and/or water.
  • the co-solvent will not be as volatile as the low-boiling fraction it is preferred for the co-solvent to have a vapour pressure which is such that it evaporates from the droplets relatively quickly.
  • the co-solvent should preferably be semi-volatile, that is, it should have a boiling point of between 2Tj°C and 110°C at atmospheric pressure.
  • the co-solvent may be any organic or inorganic compound which has the required solvation and vapour pressure characteristics.
  • co-solvents are, in particular, semi-volatile solvents or solvent systems which are suitable for adjusting the polarity of the solution in order to alter the solvation properties.
  • the selected co-solvent or co- solvents is/are non-combustible in the combined vapour/gas system generated in the course of the method of the invention.
  • Preferred co-solvents are alcohols, such as ethanol and methanol, water, acetone, dichloromethane and other semi- volatile halogenated hydrocarbons, diethyl ether, acetonitrile, tetrahydrofuran, and aliphatic and aromatic hydrocarbon solvents having appropriate properties.
  • Ethanol, dichloromethane, diethyl ether and water are especially preferred co-solvents.
  • the co-solvent or co-solvents will preferably be present in the solution in a proportion of less than 30%, more preferably less than 20% by weight.
  • Semi- volatile substances which are not co-solvents may also be included in the solution, for example, to influence the particle morphology as described below.
  • the process may be controlled by selection of the compounds comprising the low- boiling fraction and of any semi-volatile substance such as a co-solvent which will each evaporate at a respective rate dependent upon their respective vapour pressures and upon any heat transferred to the spray plume from gas surrounding the spray plume.
  • the general types of morphologies are summarised as follows.
  • the first type is obtainable under conditions of very rapid evaporation, where particle formation is dominated by the boiling of the low-boiling fraction.
  • the boiling phenomena produces many bubbles in the precipitating material (which may be a wet slurry or gel/glass) . These can result in very porous and sponge-like solid particles.
  • the second type occurs where evaporation occurs less rapidly from the surface of the droplet.
  • a solute gradient is created across the diameter of the droplet as a result.
  • the solute precipitates at the more highly supersaturated surface if solute diffusion within the droplet is insufficient to cancel the gradient.
  • this surface crust is permeable to subsequent evaporation, or a portal is left for evaporation. If not, vapour pressure may build up and the crust may shatter. Consequently, either hollow cenospheres are produced or crust fragments.
  • the third case occurs where evaporation occurs still less rapidly from the surface of the droplet.
  • growth is allowed (generally by a slower process) to occur to produce a substantially solid particle that is, a particle containing no or few voids.
  • low evaporation rates may occur where the solution contains particular excipients or active substances. It is believed that the vapour pressure of the low boiling fraction or co- solvents may, in those cases, be reduced by association with the excipient or active substances.
  • these conditions are controlled by providing the correct evaporation rate and solution nature, and by correct choice of the composition of the low-boiling fraction the co-solvents and other liquids. Again, despite the complex nature of this phenomena, we have surprisingly shown consistent behaviour for a given set of conditions (e.g. solution composition, orifice type and temperature) .
  • the solution may also comprise one or more non-volatile substances (in addition to the active substance or active substances which will themselves be non-volatile) .
  • non-volatile substance is to be understood as referring to any substance having a vapour pressure at 20°C of not more than 0.5 kPa, more preferably not more than 0.1 kPa and most preferably not more than 0.05 kPa. Such a component will not evaporate or will evaporate only slowly from the droplets and will therefore be present at least to some extent in the particles. The inclusion of one or more non-volatile substances in addition to the active substance will therefore generally lead to the formation of larger particles than would otherwise be the case.
  • the purpose of the non-volatile substance (s) may essentially be to influence the particle morphology, and/or to act to stabilise the active substance during spray-drying and/or during storage, pH modifiers or spray nozzle valve lubricants.
  • the non-volatile substance is an excipient, that is, a material which in combination with the powder forms a solid product at room temperature and which is not pharmaceutically active.
  • the excipient may act as a solubilising aid for the active substance or for any other excipients, for example, the excipient may be oligolactic acid or polylactic acid (as described in Respiratory Drug Delivery VII, 2000, pages 83- 89) , a polyoxyethylene-based dispersant, a polyester-based dispersant, oleic acid, a bile acid, an ethoxylate of oleyl alcohol or polyvinylpyrrolidone .
  • the excipient may be a dispersal agent for the promotion of the dispersal of the particles, upon actuation of the inhaler device.
  • the dispersal agent includes one or more compounds selected from amino acids and derivatives thereof, and peptides and polypeptides having molecular weight from 0.25 to 1000 KDa, and derivatives thereof. It is particularly advantageous for the dispersal agent to comprise an amino acid.
  • the dispersal agent may comprise a phospholipid or a derivative thereof for example, - li the dispersal agent may be a lecithin such as soya lecithin.
  • the dispersal agent may comprise one or more surface active materials, in particularly materials that are surface active in the solid state, which may be water soluble, for example lecithin, in particular soya lecithin, or substantially water insoluble, for example solid state fatty acids such as lauric acid, palmitic acid, stearic acid, erucic acid, behenic acid, or derivatives (such as esters and salts) thereof.
  • surface active materials in particularly materials that are surface active in the solid state, which may be water soluble, for example lecithin, in particular soya lecithin, or substantially water insoluble, for example solid state fatty acids such as lauric acid, palmitic acid, stearic acid, erucic acid, behenic acid, or derivatives (such as esters and salts) thereof.
  • magnesium stearate examples include: magnesium stearate; sodium stearyl fumarate; sodium stearyl lactylate; phospatidylcholines, phosphatidylglycerols and other examples of natural and synthetic lung surfactants; Liposomal formulations; lauric acid and its salts, for example, sodium lauryl sulphate, magnesium lauryl sulphate; triglycerides such as Dynsan 118 and Cutina HR; and sugar esters in general.
  • Magnesium stearate is a preferred dispersal agent.
  • Other possible additive materials include talc, titanium dioxide, aluminium oxide, silicon dioxide and starch.
  • the excipient may be an agent having a strong taste or flavour such as menthol.
  • the excipient may be lactose, poloxamer, PEG 2000, or polyvinylpyrrolidone (PVP) .
  • suitable excipients include polyglycolic acid, polylactic-polygylcolic acid copolymer, hydroxy propyl methyl cellulose and other modified celluloses, fatty acids and fatty acid derivatives including fluorinated fatty acids, amino acids and derivatives, polyamino acids, peptides (e.g.
  • albumen sugars for example, mannitol, sorbitol and trehalose, PEG especially higher molecular weight-PEGs, ascorbic acid, citric acid, phospholipids and derivatives, inorganic salts, Carbopol , cyclodextrins, surfactants such as the Spans, Tweens and Pluronics and saccharin.
  • the solution may include substances known as stabilisers which stabilise proteins for example, glycerol , PEG, PVP and amino acids. Excipients such as magnesium stearate, amino acids e.g.
  • leucine, fatty acids or fatty acid derivatives and phospholipids such as lecithin may, individually or in combination, form a protective layer around the active particles, protect the active particles from moisture, make the active particles more easily disaggregated and/or impart controlled release properties on the active material .
  • Any non-volatile components will preferably be pharmaceutically acceptable.
  • a single nonvolatile substance may have more than one function when included in the solution.
  • an amino acid may stabilise a protein active material during the drying process, promote the dispersal of the particles when the particles are dispensed from an inhaler, and form a protective layer around the particles .
  • the solution will preferably be substantially free of suspended particles and emulsified liquids.
  • excipients or dispersal agents for example, magnesium stearate in the form of particles suspended in the solution of the active substance.
  • the solution may be maintained unpressurised at a temperature below its boiling point. However, that will lead to a lower rate of evaporation and it is preferred to maintain the solution at or around ambient temperature under sufficient pressure to prevent boiling. When the solution is maintained under pressure, that pressure will act to expel it from the orifice and it will often not be necessary to pump the solution through the orifice.
  • a valve or other flow regulating system may be used to control the rate of expulsion from the orifice.
  • an expansion chamber such as that present in a pressurised metered dose inhaler actuator or the like may be present as part of the nozzle system.
  • the orifice communicates with a chamber.
  • the chamber may be of the type used in conventional spray drying having for example, an approximately cylindrical upper section and a tapering lower section.
  • the dimensions and shape of the chamber will preferably be such that the droplets may circulate within it and dry to form particles whilst keeping impacts with the walls of the chamber to a minimum.
  • the evaporation of the low-boiling fraction and any co-solvent present in the droplets will require the input of heat energy corresponding to at least the heat of vaporisation of those substances .
  • a current of carrier gas may be injected into the chamber.
  • the current of carrier gas which is preferably air, serves to promote a swirling motion of the droplets and increases the rate of drying and keeps them airborne whilst they dry.
  • the current of gas may also serve to carry the particles through the apparatus to a separator, where the particles are separated from the gas.
  • the current of gas may be at ambient temperature or alternatively, where it is desired to increase the rate of evaporation, the current of carrier gas may be of a heated gas.
  • the flow of the gases in the chamber is substantially laminar in order to minimise agglomeration.
  • the pressure in the chamber may be maintained at below atmospheric pressure. This increases the rate of evaporation and also prevents leaks of the vapour from the chamber.
  • vapour refers to the products of the evaporation of the volatile components of the solution, that is the low-boiling fraction, any co-solvents and any other volatile components.
  • gas refers to gases, such as air or nitrogen, which have not been derived from evaporation or boiling of the liquids of the solution.
  • the particles will be in the form of a cloud or dispersion entrained with the vapours of the evaporated low-boiling fraction and co-solvents, if present, and optionally with a carrier gas such as air or nitrogen. It is then necessary to
  • the separation may be a settling process in which the particles fall under gravity.
  • the aerodynamic diameter of the particles is very small, for example, less than lO ⁇ m, such settling processes will be slow and it is therefore
  • the step of collecting the particles may involve a filter, for example, a bag filter, a cartridge filter or a sintered metal filter.
  • the filter is a reverse jet filter to enable
  • the step of collecting the particles preferably involves a cyclone, and advantageously involves an impactor or virtual impactor. In some cases it will be desirable to use a combination of two or more of those methods of separation, for example the
  • J5 gas/vapour/particle mixture may be passed through one or more cyclones and then through a bag filter. This may be conducted to selectively fractionate and collect more than one size fraction, where a specifically narrow or selected size fraction is required.
  • the size of the particles produced will to some extent depend on the droplet size which will in turn be determined by such variables as the size and configuration of the orifice, the properties (such as surface tension, viscosity, and concentration of the active substance) of the solution, the vapour pressure of the liquid, the size and shape of the orifice and design of the nozzle,
  • the particles be used as drug particles in a medicament formulation for pulmonary administration, at least 50% and preferably 90% by weight of
  • the particles should in general have an aerodynamic diameter of less than lO ⁇ m, preferably less than 5 ⁇ m and more preferably less than 2 ⁇ m (in order that they penetrate to the lower lung) .
  • the lower limit of the diameter may be as small as lnm but is advantageously greater than O.Ol ⁇ m (particles of
  • the particles are intended for use in needle-less injections, that is, to be carried through the skin by a blast of propellant gas, they will desirably have diameters of not
  • composition of the solution and the conditions of evaporation may be selected so as to produce hollow or porous particles. Such particles will have a lower aerodynamic diameter than a particle of the same mass which is not hollow
  • the solution also comprises a non-volatile substance, for example, an excipient which, as the agglomerate forms, provides a whole or partial coating on the surface of the agglomerates which increases the texturing or roughness of the surface.
  • the solution of the active substance and/or the particles of the active substance are not liposomal formulations .
  • the low-boiling fraction is recycled, for example, by feeding the vapours after separation of the particles into compression or refrigeration apparatus which will condense the low-boiling fraction.
  • the co-solvents may also be recycled.
  • the method of the invention is run as a continuous process over a period of at least one minute, advantageously at least 5 minutes, more preferably at least one hour. Preferably, within that time, the process produces at least 0.5g of particles, more preferably at least 5g of particles .
  • the active substance is a medicinal substance, that is, a substance which has therapeutic or prophylactic effects. Active substances which may advantageously be included in the formulation include those products which are usually administered orally by inhalation for the treatment of disease such as respiratory disease, for example, ⁇ -agonists.
  • the active substances may be a ⁇ 2 -agonist, for example, terbutaline, salbuta ol, salmeterol and formoterol. If desired, the solution may comprise more than one of those active substances, provided that they are compatible with one another under conditions of storage and use.
  • the active substance is salbutamol sulphate.
  • the active substance may be ipratropium bromide. References herein to any active substance is to be understood to include any physiologically acceptable derivative. In the case of the ⁇ 2 -agonists mentioned above, physiologically acceptable derivatives include salts, especially sulphates.
  • the active substance may be a steroid, which may be beclomethasone dipropionate, budesonide, or fluticasone.
  • the active substance may include a cromone which may be sodium cromoglycate or nedocromil .
  • the active substance may include a leukotriene receptor antagonist.
  • the active substance may be a carbohydrate, for example heparin.
  • Active particles for pulmonary administration may advantageously comprise an active substance for systemic use provided that it is capable of being absorbed into the circulatory system via the lungs.
  • the particles may be suitable for use for the local administration of other active substances, for example, pain relief agents, anti -cancer agents, anti-viral agents or antibiotics.
  • the active substance is a biological macromolecule, for example, a polypeptide, a protein, or a DNA fragment.
  • the active substance may be selected from the group consisting of insulin, human growth hormone, cytokines, cyclosporin, interferon, gonadotrophin agonists and antagonists, erythropoietin, leptin, antibodies, vaccines, antisense oligonucleotides, calcitonin, somotastatin, parathyroid hormone, alpha-1-antitrypsin, Factor 7, Factor 8, Factor 9, and estradiol .
  • the active substance is selected from the group consisting of insulin, human growth hormone, cytokines, cyclosporin, interferon, gonadotrophin agonists and antagonists, erythropoietin, leptin, antibodies, vaccines and antisense oligonucleotides.
  • the invention also provides a powder comprising particles comprising an active substance obtainable by the method described above.
  • particles may be porous or hollow or may have surface projections or wrinkles. It is believed that the presence of surface projections or wrinkles reduces the forces of attraction between the particles and thereby reduces the cohesiveness of the particles and enables those particles to be dispersed more easily, for example during pulmonary administration.
  • Pollen grains are known to have surface projections and it is believed that those projections similarly aid in the dispersal of pollen into the air.
  • the process of the invention may provide particles having a pollen-like surface morphology.
  • the powder may advantageously have a density which is less than 70%, for example less than 50%, preferably less than 25%, most preferably less than 10% of the density of the solid material having the same composition as the powder.
  • the density of the powder as referred to herein will be understood to be the density of a sample of a powder consisting of the particles and may be measured by pouring a known weight, for example 50g, of the powder into a measuring cylinder, tapping the cylinder until the powder settles to constant volume and measuring the volume of the powder.
  • the density of the solid material will, in general, be known but may be measured by any suitable method.
  • the particles according to the invention may be suitable for subsequent use in any administration form, but are especially advantageous for use in pressurised metered dose inhalers, dry powder inhalers or needle-less injection devices. If appropriate or if desired, the particles may undergo subsequent processing and formulation steps before their use in such applications.
  • the invention also provides a pharmaceutical composition, for example, a composition for inhalation comprising a powder according to the invention.
  • the composition for inhalation may be a dry powder for use in a dry powder inhaler.
  • the powder according to the invention may be used alone or may be mixed with other dry materials such as excipients, flavour modifiers and flow aids.
  • the composition for inhalation may comprise a propellant and be suitable for use in a pressurised 5 metered dose inhaler.
  • the powder will be present as a suspension in the propellant.
  • Such formulations may contain other materials such as dispersents, and surfactants.
  • the powders according to the invention can, in general, be included in compositions for inhalation in the same way as -0 for currently known milled icronised drug powders and therefore the development of appropriate formulations will be within the ability of the skilled person.
  • Figure 1 is a schematic representation of an apparatus for carrying out a method according to the invention
  • Figure 2 is a scanning electron micrograph (SEM) image of particles of beclomethasone diproprionate made using one form JO of method according to the invention
  • Figure 3 is a SEM image of particles of beclomethasone dipropionate similar to those of Figure 2 but at higher magnification;
  • FIG 4 is a SEM image of particles of budesonide .
  • a system for manufacturing the particles comprises a reservoir 1 for holding the solution.
  • the reservoir 1 is equipped with means 2 for stirring the solution.
  • the reservoir and its immediate location are within a temperature control zone 3 , in which a SO constant temperature is maintained (including the reservoir and contents) .
  • the solution is introduced into the reservoir through an inlet pipe (not shown) and leaves the reservoir via an outlet pipe 4, which leads to a single fluid nozzle 5.
  • a valve 6 or other flow regulating system may be used to control the rate of expulsion from the orifice.
  • An expansion chamber (not shown) may be present as part of the nozzle system.
  • the nozzle 5 is located in the upper region of a spray chamber 7 5 and is surrounded by carrier gas which has been heated to the required temperature and introduced into the chamber via carrier gas line 8 and gas inlets 9.
  • the reservoir 1 and the nozzle system 5, and the drying chamber 7 may be independently maintained at different temperatures.
  • the embodiment shown is a cascade of cyclones 11 which separates the majority of the particles from the gas/vapour stream.
  • an inertial classifier or a virtual impactor may be used as well as or instead of the cyclones.
  • the gas/vapour stream then passes through a high efficiency
  • the vapour/gas mixture then passes into a refrigerated zone 13 where the vapours are condensed and collected for recycling.
  • the gases and residual vapour are then fed to an exhaust.
  • Reference numeral 14 designates a pump.
  • the reservoir 1
  • Temperature control zone 3 is wholly contained within temperature control zone 15 and may be maintained independently at a different temperature
  • the carrier gas will be fed into the chamber inlet under positive pressure, driven by, for example, a fan.
  • a gas pump will be provided in the region of the exhaust. The suction of the gas pump will draw the carrier gas through the system. In either case, the carrier gas carries the vapour and particles through the system.
  • Beclamethasone diproprionate (BDP) was dissolved in an 85:15 by weight hydrofluorocarbon 134a: ethanol mixture to form a 0.5% w/w solution. That composition was maintained at 25°C in a reservoir at about 7 bar and sprayed at a spray rate of 50 ⁇ l/sec through a nozzle having a circular orifice into a 2 litre vessel. The vessel was maintained at approximately 25°C by heating carrier air, which was pumped into the vessel at a flow rate of 50 1pm. The particles formed were separated from the air/vapour steam by means of drawing them onto a filter using a pump. The particles so obtained are shown in Figure 2. The particles were substantially in the size range of 0.5 to lO ⁇ m and had a highly porous structure. Figure 3 shows at higher magnification than Figure 2 particles of beclamethasone diproprionate made by a similar method.
  • a powder for inhalation was then prepared by mixing lg of the beclamethasone diproprionate powder with 9g of a coarse carrier lactose in a tumbling mixer for 5 minutes at 42rpm.
  • the resulting powder was suitable for firing from a suitable inhaler device such as the Cyclohaler.
  • In vitro tests for example in a twin stage impinger, gave a fine particle fraction (i.e. having a diameter of less than 5 ⁇ m) of greater than 50%.
  • Insulin is dissolved in a mixture of hydroflurocarbon 227 with ethanol and water as co-solvents (85:7.5:7.5) to give a 0.5% w/w solution of insulin.
  • the solution is maintained at 25°C in a reservoir and sprayed from the reservoir into a vessel maintained at approximately 35°C by heating the carrier air. Dry particles of insulin are produced.
  • a powder for inhalation comprising the insulin particles is produced in the same way as for Example 1.
  • Budesonide was dissolved in a mixture of 85 parts of hydrofluorocarbon 134a and 15 parts of ethanol. The concentration of budesonide was approximately 0.1% w/w. The solution was maintained at 25°C and sprayed from the reservoir into a vessel maintained at approximately 25°C by heating the carrier air. Dry particles were produced. The particles, shown in Figure 4, were substantially in the size range of from 0.5 to 3 ⁇ m, and visibly more dense than the particles obtained in Example 1.
  • a powder for inhalation comprising the budesonide powder may be prepared by the method of Example 1.
  • Cyclosporin is dissolved in a mixture (85:15) of hydrofluorocarbon 227 with ethanol as co-solvent.
  • the composition is maintained at 25°C and sprayed from the reservoir with a vessel maintained at approximately 35°C by heating the carrier air. Dry particles are produced.
  • the cyclosporin powder may be included in a powder for inhalation by the same method as in Example 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des poudres de matière active sur le plan pharmaceutique. Le procédé de préparation de ces poudres consiste d'abord à fournir une solution qui contient cette matière active et une fraction à bas point d'ébullition, à expulser ensuite cette solution par un orifice pour former des gouttelettes, puis à permettre à la fraction à bas point d'ébullition de s'évaporer, et enfin, à collecter les particules ainsi formées. On peut utiliser ces poudres dans des poudres médicinales à inhaler.
PCT/GB2001/002137 2000-05-15 2001-05-15 Procede de fabrication de particules WO2001087277A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001254995A AU2001254995A1 (en) 2000-05-15 2001-05-15 Method of manufacturing particles

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0011712.7 2000-05-15
GB0011712A GB0011712D0 (en) 2000-05-15 2000-05-15 Method of manufacturing particles
GB0029265A GB0029265D0 (en) 2000-11-30 2000-11-30 Method of manufacturing particles
GB0029265.6 2000-11-30

Publications (2)

Publication Number Publication Date
WO2001087277A2 true WO2001087277A2 (fr) 2001-11-22
WO2001087277A3 WO2001087277A3 (fr) 2002-04-04

Family

ID=26244273

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/002137 WO2001087277A2 (fr) 2000-05-15 2001-05-15 Procede de fabrication de particules

Country Status (2)

Country Link
AU (1) AU2001254995A1 (fr)
WO (1) WO2001087277A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073827A1 (fr) * 2003-02-21 2004-09-02 The University Of Bath Procede de production de particules
WO2009095681A2 (fr) * 2008-02-01 2009-08-06 Vectura Limited Formulations pour suspensions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021688A1 (fr) * 1994-02-15 1995-08-17 Eckhard Weidner Procede pour la fabrication de particules ou de poudres
WO1998016204A1 (fr) * 1996-10-14 1998-04-23 F. Hoffmann-La Roche Ag Procede destine a la fabrication d'une preparation en poudre
WO1999016419A1 (fr) * 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Microparticules perforees et procedes d'utilisation
WO1999042124A1 (fr) * 1998-02-20 1999-08-26 Inhale Therapeutic Systems, Inc. Cyclosporine en cristaux liquides
WO2000000176A1 (fr) * 1998-06-30 2000-01-06 Quadrant Healthcare (Uk) Limited Formulation a microparticules pour inhalation
WO2000074653A1 (fr) * 1999-06-04 2000-12-14 Skyepharma, Inc. Compositions a noyau huileux destinees a la liberation prolongee de medicaments hydrophobes
WO2001003671A2 (fr) * 1999-07-13 2001-01-18 Skw Trostberg Aktiengesellschaft Procede de preparation de formulations pulverulentes a taux particulaire reduit a l'aide de gaz comprimes

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021688A1 (fr) * 1994-02-15 1995-08-17 Eckhard Weidner Procede pour la fabrication de particules ou de poudres
WO1998016204A1 (fr) * 1996-10-14 1998-04-23 F. Hoffmann-La Roche Ag Procede destine a la fabrication d'une preparation en poudre
WO1999016419A1 (fr) * 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Microparticules perforees et procedes d'utilisation
WO1999042124A1 (fr) * 1998-02-20 1999-08-26 Inhale Therapeutic Systems, Inc. Cyclosporine en cristaux liquides
WO2000000176A1 (fr) * 1998-06-30 2000-01-06 Quadrant Healthcare (Uk) Limited Formulation a microparticules pour inhalation
WO2000074653A1 (fr) * 1999-06-04 2000-12-14 Skyepharma, Inc. Compositions a noyau huileux destinees a la liberation prolongee de medicaments hydrophobes
WO2001003671A2 (fr) * 1999-07-13 2001-01-18 Skw Trostberg Aktiengesellschaft Procede de preparation de formulations pulverulentes a taux particulaire reduit a l'aide de gaz comprimes

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073827A1 (fr) * 2003-02-21 2004-09-02 The University Of Bath Procede de production de particules
WO2009095681A2 (fr) * 2008-02-01 2009-08-06 Vectura Limited Formulations pour suspensions
WO2009095681A3 (fr) * 2008-02-01 2010-05-14 Vectura Limited Formulations pour suspensions
US9011923B2 (en) 2008-02-01 2015-04-21 Innovata Biomed Limited Suspension formulations

Also Published As

Publication number Publication date
WO2001087277A3 (fr) 2002-04-04
AU2001254995A1 (en) 2001-11-26

Similar Documents

Publication Publication Date Title
TWI290473B (en) Phospholipid-based powders for drug delivery
US9439862B2 (en) Phospholipid-based powders for drug delivery
JP5372306B2 (ja) 多孔性微粒子および使用方法
DE69725308T2 (de) Verfahren und vorrichtung zur inhalation teilchenförmiger medikamente
US20020017295A1 (en) Phospholipid-based powders for inhalation
EP0951300A1 (fr) Procedes permettant de secher par pulverisation des solutions de medicaments hydrophobes et d'excipients hydrophiles et compositions preparees selon ces procedes
JP2000510471A (ja) 分散性高分子組成物並びにそれらの調製及び使用のための方法
CA2405659A1 (fr) Composition particulaire
AU780327B2 (en) Spray drying process for preparing dry powders
GB2388541A (en) Aerosol formulations comprising a particulate active substance suspended in a hydrofluorocarbon
WO2001087277A2 (fr) Procede de fabrication de particules
El-Gendy et al. Particle engineering technologies for pulmonary drug delivery
Rowe et al. Compositions and methods of making brittle-matrix particles through blister pack freezing
EP2340816A1 (fr) Installation pour la fabrication de particules support composites
Barron Investigation of formulation and processing technique on the characteristics of polymeric powders produced for suspension type pressurized metered dose inhaler systems
Chow et al. Expert Review
Cocks The Delivery of Porous Poly (DL-Lactide-co-Glycolide) Microspheres Via Pressurised Metered Dose Inhaler Suspensions
MXPA00003105A (en) Perforated microparticles and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP